Rivaroxaban

[references-standards] Rivaroxaban
  • Référence produit : C2138
  • Numéro de CAS : 366789-02-8
  • Formule moléculaire : C19H18ClN3O5S
  • Masse molaire : 435,88 g.mol-1
  • Pureté min. : 98,00 %
  • Solubilité : se référer au COA
  • Stabilité : ≥ 1 an
  • Expédition : 24/48h pour les produits en stock
Faire une demande
Référence du produit : C2138
Masse
Qté

Description

Rivaroxaban is intended for Pharmaceuticals applications. It is an orally active, direct inhibitor of Factor Xa and a novel antithrombotic agent. All information about Rivaroxaban is provided in the MSDS. We deliver compounds with high purity levels and a comprehensive Certificate of Analysis. Connect to your member account to consult the documents.

Produits liés

Références

  1. Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects? Blood Coagul Fibrinolysis. 2015 Dec; 26(8): 925–933. [...]
  2. Rivaroxaban Delivery and Reversal at a Venous Flow Rate Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32:2877–2883 [...]
  3. Efficacy of pro- and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery J Thromb Haemost. 2020;18:2840–2851 [...]
  4. Invasive Infections with Nannizziopsis obscura Species Complex in 9 Patients from West Africa, France, 2004–20201 Emerg Infect Dis. 2020 Sep; 26(9): 2022–2030 [...]
  5. A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies Journal of Chromatography B Volume 1144, 1 May 2020, 122095 [...]
  6. In vitro assessment of P-gp and BCRP transporter-mediated drug–drug interactions of riociguat with direct oral anticoagulants fundamental & clinical pharmacology, volume 34, issue 1, February 2020, p. 109-119 [...]
  7. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban European Journal of Pharmaceutics and Biopharmaceutics Volume 148, March 2020, Pages 27-37 [...]
  8. Resolving DOAC interference on antithrombin activity testing on a FXa based method by the use of activated carbon. Clinica Chimica Acta - Volume 538, 1 January 2023, Pages 216-220 [...]

Recommandation